Patents by Inventor Mark Throsby

Mark Throsby has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12291798
    Abstract: Provided are methods for efficiently and comprehensively screening antibody repertoires from B cells to obtain and produce molecules with binding characteristics and functional activities for use in human therapy.
    Type: Grant
    Filed: August 5, 2022
    Date of Patent: May 6, 2025
    Assignee: Merus N.V.
    Inventors: Mark Throsby, Ton Logtenberg, John De Kruif
  • Patent number: 12247078
    Abstract: The invention relates to the field of antibodies. In particular it relates to the field of therapeutic (human) antibodies for the treatment of ErbB-2/ErbB-3 positive cells. More in particular it relates to treating of cells comprising an NRG1 fusion gene comprising at least a portion of the NRG1-gene fused to a sequence from a different chromosomal location.
    Type: Grant
    Filed: February 21, 2024
    Date of Patent: March 11, 2025
    Assignee: Merus N.V.
    Inventors: Mark Throsby, Cecilia Anna Wilhelmina Geuijen, David Andre Baptiste Maussang-Detaille, Ton Logtenberg
  • Patent number: 12139548
    Abstract: The invention relates among others to antibodies comprising a first antigen-binding site that binds Erb B-2 and a second antigen-binding site that binds Erb B-3. The antibodies can typically reduce a ligand-induced receptor function of Erb B-3 on a Erb B-2 and Erb B-3 positive cell. Also described are method for the treatment and use of the antibodies in imaging and in the treatment of subjects having an Erb B-2, Erb B-3 or Erb B-2/3 positive tumor.
    Type: Grant
    Filed: October 19, 2022
    Date of Patent: November 12, 2024
    Assignee: Merus N.V.
    Inventors: Cecilia Anna Wilhelmina Geuijen, Cornelis Adriaan De Kruif, Mark Throsby, Ton Logtenberg, Alexander Berthold Hendrik Bakker
  • Patent number: 12091461
    Abstract: A bispecific antibody which is capable of specifically binding to PD-1 and CD3 is disclosed. The bispecific antibody is suitable for preventing, suppressing symptom progression or recurrence of, and/or treating autoimmune diseases. Also disclosed is a formulation which can reduce occurrence of adverse infusion reactions or adverse reaction called cytokine release syndrome. The bispecific antibody has the feature to allow interaction between PD-1 and PD-L1 as its ligand, contributes enhancement or duration of its effects.
    Type: Grant
    Filed: July 2, 2021
    Date of Patent: September 17, 2024
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shiro Shibayama, Takuya Shimbo, Tomoya Tezuka, Mark Throsby, Cornelis Adriaan de Kruif, Pieter Fokko van Loo, Rinse Klooster
  • Publication number: 20240287187
    Abstract: A bispecific antibody which is capable of specifically binding to PD-1 and CD3 is disclosed. The bispecific antibody is suitable for preventing, suppressing symptom progression or recurrence of, and/or treating autoimmune diseases. Also disclosed is a formulation which can reduce occurrence of adverse infusion reactions or adverse reaction called cytokine release syndrome. The bispecific antibody has the feature to allow interaction between PD-1 and PD-L1 as its ligand, contributes enhancement or duration of its effects.
    Type: Application
    Filed: April 30, 2024
    Publication date: August 29, 2024
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shiro SHIBAYAMA, Takuya Shimbo, Tomoya Tezuka, Mark Throsby, Cornelis Adriaan DE Kruif, Pieter Fokko van Loo, Rinse Klooster
  • Patent number: 11939394
    Abstract: The invention provides means and methods for inhibiting growth of a cancer. The means in some embodiments comprise proteins and antibodies that binds an extracellular part of a membrane associated member of the epidermal growth factor (EGF) receptor family and an extracellular part of a membrane associated member of a WNT signaling pathway. Further provided are various cells and assays that are helpful in the production of the proteins, antibodies and cells.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: March 26, 2024
    Assignees: Merus N.V., Fundacio Institut de Recerca Biomedica, Institució Catalana de Recerca I Estudis Avancats
    Inventors: Mark Throsby, Ton Logtenberg, Johannes Carolus Clevers, Robert Gerhardus Jacob Vries, Eduard Batlle, Bram Herpers
  • Publication number: 20240023527
    Abstract: Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is human, human-like, or humanized. The nucleic acid is provided with a means that renders it resistant to DNA rearrangements and/or somatic hypermutations. In one embodiment, the nucleic acid comprises an expression cassette for the expression of a desired molecule in cells during a certain stage of development in cells developing into mature B cells. Further provided is methods for producing an immunoglobulin from the transgenic, non-human animal.
    Type: Application
    Filed: September 1, 2023
    Publication date: January 25, 2024
    Applicant: Merus N.V.
    Inventors: Ton LOGTENBERG, Mark Throsby, Robert A. Kramer, Rui D. Pinto, Cornelis A. De Kruif, Erwin Houtzager
  • Patent number: 11820825
    Abstract: The invention relates in one aspect to bispecific antibodies comprising a first antigen-binding site that binds EGFR and a second antigen-binding site that binds Erb B-3, wherein the antibody has a half maximal growth inhibitory concentration (IC50) of less than 200 pM for inhibiting EGFR and/or Erb B-3 ligand induced growth of Bx PC3 cells or Bx PC3-luc2 cells. Further described are method for producing the bispecific antibodies and means and methods for the treatment of subjects with the antibodies.
    Type: Grant
    Filed: October 21, 2020
    Date of Patent: November 21, 2023
    Assignee: Merus N.V.
    Inventors: Ton Logtenberg, Mark Throsby, Robertus Cornelis Roovers
  • Patent number: 11785924
    Abstract: Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is human, human-like, or humanized. The nucleic acid is provided with a means that renders it resistant to DNA rearrangements and/or somatic hypermutations. In one embodiment, the nucleic acid comprises an expression cassette for the expression of a desired molecule in cells during a certain stage of development in cells developing into mature B cells. Further provided is methods for producing an immunoglobulin from the transgenic, non-human animal.
    Type: Grant
    Filed: January 5, 2018
    Date of Patent: October 17, 2023
    Assignee: Merus N.V.
    Inventors: Ton Logtenberg, Mark Throsby, Robert A. Kramer, Rui Daniel Pinto, Cornelis A. De Kruif, Erwin Houtzager
  • Patent number: 11780925
    Abstract: The invention relates to the field of antibodies. In particular it relates to the field of therapeutic (human) antibodies for the treatment of ErbB-2/ErbB-3 positive cells. More in particular it relates to treating of cells comprising an NRG1 fusion gene comprising at least a portion of the NRG1-gene fused to a sequence from a different chromosomal location.
    Type: Grant
    Filed: April 3, 2018
    Date of Patent: October 10, 2023
    Inventors: Mark Throsby, Cecilia Anna Wilhelmina Geuijen, David Andre Baptiste Maussang-Detaille, Ton Logtenberg
  • Patent number: 11773170
    Abstract: The invention as disclosed herein relates to bispecific antibodies that comprises a first variable domain that can bind an extracellular part of epidermal growth factor receptor (EGFR) and a second variable domain that can bind an extracellular part of MET Proto-Oncogene, Receptor Tyrosine Kinase (cMET). The antibody may comprise a common light chain. It may be a human antibody. The antibody may be a full length antibody. In some embodiments the bispecific antibody is an IgG1 format antibody having an anti-EGFR, anti-cMET stoichiometry of 1:1. In some embodiment the antibody has one variable domain that can bind EGFR and one variable domain that can bind cMET.
    Type: Grant
    Filed: August 9, 2018
    Date of Patent: October 3, 2023
    Inventors: Cecilia Anna Wilhelmina Geuijen, Robertus Cornelis Roovers, Mark Throsby, Cornelis Adriaan De Kruif, Ton Logtenberg
  • Patent number: 11753470
    Abstract: The disclosure provides means and methods for interfering with Programmed Cell Death 1 protein (PD-1) and T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) mediated inhibition in a PD-1 and/or TIM-3 positive cell. A method may comprise contacting said cell with an antibody or a functional part, derivative and/or analogue thereof that comprises a variable domain that can bind to an extracellular part of PD-1 and a variable domain that can bind to an extracellular part of TIM-3, thereby inhibiting PD-1 and/or TIM-3 mediated activity in said cell. The invention also provides antibodies or variants thereof that comprises a variable domain that can bind to an extracellular part of PD-1 and a variable domain that can bind to an extracellular part of TIM-3.
    Type: Grant
    Filed: July 6, 2018
    Date of Patent: September 12, 2023
    Inventors: Cecilia Anna Wilhelmina Geuijen, Rinse Klooster, Cornelis Adriaan De Kruif, Paulus Johannes Tacken, Mark Throsby, Ton Logtenberg
  • Patent number: 11732043
    Abstract: The invention provides means and methods for interfering with Programmed Cell Death 1 protein (PD-1) and Lymphocyte activation 3 (LAG 3) mediated inhibition in a PD-1 and/or LAG3 positive cell. A method may comprise contacting said cell with an antibody or a functional part, derivative and/or analogue thereof that comprises a variable domain that can bind to an extracellular part of PD-1 and a variable domain that can bind to an extracellular part of LAG3, thereby inhibiting PD-1 and/or LAG3 mediated activity in said cell. The invention also provides antibodies or variants thereof that comprises a variable domain that can bind to an extracellular part of PD-1 and a variable domain that can bind to an extracellular part of LAG3.
    Type: Grant
    Filed: July 6, 2018
    Date of Patent: August 22, 2023
    Assignee: MERUS N.V.
    Inventors: Cecilia Anna Wilhelmina Geuijen, Rinse Klooster, Cornelis Adriaan De Kruif, Paulus Johannes Tacken, Mark Throsby, Ton Logtenberg
  • Patent number: 11685786
    Abstract: The invention provides means and methods of stimulating activity of a member of the TNF receptor superfamily on a cell. The invention also provides binding molecules such as antibodies that comprises at least two antigen binding sites, wherein a first antigen binding site can bind an extracellular part of CD137 and a second antigen binding site can bind an extracellular part of PD-L1.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: June 27, 2023
    Assignee: MERUS N.V.
    Inventors: Cecilia Anna Wilhelmina Geuijen, Mark Throsby, Cornelis Adriaan De Kruif, Rinse Klooster, Paulus Johannes Tacken, Ton Logtenberg
  • Patent number: 11667714
    Abstract: The invention provides means and methods for inhibiting a biological activity of cells. In one embodiment the invention is concerned with a method of inhibiting a biological activity in a first or second cell mediated by the binding of two membrane proteins that are binding partners for each other. The mentioned biological activity is inhibited by providing the cells with an antibody or antibody like molecule that can bind to each of the mentioned binding partners and the binding blocks the binding of the two binding partners thereby inhibiting the mentioned biological activity.
    Type: Grant
    Filed: July 6, 2018
    Date of Patent: June 6, 2023
    Assignee: Merus N.V.
    Inventors: Cecilia Anna Wilhelmina Geuijen, Rinse Klooster, Cornelis Adriaan De Kruif, Paulus Johannes Tacken, Mark Throsby, Ton Logtenberg
  • Patent number: 11559049
    Abstract: Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is human, human-like, or humanized. The nucleic acid is provided with a means that renders it resistant to DNA rearrangements and/or somatic hypermutations. In one embodiment, the nucleic acid comprises an expression cassette for the expression of a desired molecule in cells during a certain stage of development in cells developing into mature B cells. Further provided is methods for producing an immunoglobulin from the transgenic, non-human animal.
    Type: Grant
    Filed: January 12, 2018
    Date of Patent: January 24, 2023
    Assignee: Merus N.V.
    Inventors: Ton Logtenberg, Mark Throsby, Robert A. Kramer, Rui D. Pinto, Cornelis A. De Kruif, Erwin Houtzager
  • Patent number: 11445710
    Abstract: Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is human, human-like, or humanized. The nucleic acid is provided with a means that renders it resistant to DNA rearrangements and/or somatic hypermutations. In one embodiment, the nucleic acid comprises an expression cassette for the expression of a desired molecule in cells during a certain stage of development in cells developing into mature B cells. Further provided is methods for producing an immunoglobulin from the transgenic, non-human animal.
    Type: Grant
    Filed: January 12, 2018
    Date of Patent: September 20, 2022
    Assignee: Merus N.V.
    Inventors: Ton Logtenberg, Mark Throsby, Robert A. Kramer, Rui D. Pinto, Cornelis A. De Kruif, Erwin Houtzager
  • Patent number: 11408095
    Abstract: Provided are methods for efficiently and comprehensively screening antibody repertoires from B cells to obtain and produce molecules with binding characteristics and functional activities for use in human therapy.
    Type: Grant
    Filed: April 17, 2020
    Date of Patent: August 9, 2022
    Assignee: Merus N.V.
    Inventors: Mark Throsby, Ton Logtenberg, John De Kruif
  • Patent number: 11279770
    Abstract: The invention relates among others to antibodies comprising a first antigen-binding site that binds Erb B-2 and a second antigen-binding site that binds Erb B-3. The antibodies can typically reduce a ligand-induced receptor function of Erb B-3 on a Erb B-2 and Erb B-3 positive cell. Also described are method for the treatment and use of the antibodies in imaging and in the treatment of subjects having an Erb B-2, Erb B-3 or Erb B-2/3 positive tumor.
    Type: Grant
    Filed: February 27, 2015
    Date of Patent: March 22, 2022
    Assignee: Merus N.V.
    Inventors: Cecilia Anna Wilhelmina Geuijen, Cornelis Adriaan De Kruif, Mark Throsby, Ton Logtenberg, Alexander Berthold Hendrik Bakker
  • Patent number: 11237165
    Abstract: Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is a common human, human-like, or humanized light chain. Further provided is methods for producing an immunoglobulin from the transgenic, non-human animal.
    Type: Grant
    Filed: July 18, 2017
    Date of Patent: February 1, 2022
    Assignee: Merus N.V.
    Inventors: Ton Logtenberg, Mark Throsby, Robert A. Kramer, Rui Daniel Pinto, Cornelis A. de Kruif, Erwin Houtzager